Favorable response to third-generation TKI furmonertinib in a patient with early-stage non-small cell lung cancer harboring rare compound EGFR mutations: Exon 18 G719C and Exon 20 S768I — A Case Report
EGFR Exon 19 deletions and exon 21 point mutations of EGFR are the most prevalent alterations in lung adenocarcinoma, and patients with these mutations derive substantial clinical benefit from EGFR tyrosine kinase inhibitors (TKIs). Nevertheless, the therapeutic efficacy of TKIs in rare compound EGF...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Frontiers Media S.A.
2026-01-01
|
| Rangatū: | Frontiers in Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1714432/full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|